INTERVIEW: Regulus CEO Xanthopoulos on IPO, 'Road to the Clinic'
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics president and CEO Kleanthis Xanthopoulos says – half-joking, half-serious – that he's glad the San Diego-based developer of medicines targeting microRNA went public when it did last year, because he likes to be a trendsetter.